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Available online 11 June 2016Retinoic acid inducible gene-I (RIG-I) is a cytosolic pathogen recognition receptor that initiates the immune re-
sponse against many RNA viruses. Upon RNA ligand binding, RIG-I undergoes a conformational change facilitat-
ing its homo-oligomerization and activation that results in its translocation from the cytosol to intracellular
membranes to bind its signaling adaptor protein, mitochondrial antiviral-signaling protein (MAVS). Here we
show that RIG-I activation is regulated by reversible acetylation. Acetyl-mimetic mutants of RIG-I do not form
virus-induced homo-oligomers, revealing that acetyl-lysine residues of the RIG-I repressor domain prevent as-
sembly to active homo-oligomers. During acute infection, deacetylation of RIG-I promotes its oligomerization
upon ligand binding. We identify histone deacetylase 6 (HDAC6) as the deacetylase that promotes RIG-I activa-
tion and innate antiviral immunity to recognize and restrict RNA virus infection.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Innate immunity1. Introduction
Retinoic acid inducible gene-I (RIG-I) plays a major role in pathogen
recognition to trigger innate immunity and signal the initiation of the
immune response against RNA virus infection. RIG-I is the prototypical
member of the RIG-I-like receptor (RLR) family of cytosolic RNA
helicases includes melanoma differentiation-associated gene 5
(MDA5) and laboratory of genetics and physiology 2 (LGP2) proteins.
RIG-I functions as a cytosolic pathogen recognition receptor (PRR)
(Loo andGale, 2011) and drives immune signaling after binding to path-
ogen associatedmolecular pattern (PAMP)motifs within viral RNA that
accumulate during acute infection of many RNA viruses (Kell et al.,
2015). RIG-I recognizes 5′-triphosphate (5′-ppp) in conjunction with
double-stranded (ds) RNA as non-self PAMPs. Our studies have shown
that during acute hepatitis C virus (HCV) infection RIG-I recognizes
and binds to the poly-uridine/cytosine (poly-U/UC) motif of the HCV
RNA, thus signaling an innate immune response that restricts hepato-
cyte permissiveness for infection (Schnell et al., 2012; Saito et al.,aboratory Sciences and Medical
rsity Bldg.Lab.Med., Rm437 No.
uw.edu (M. Gale).
. This is an open access article under2008). Active RIG-I then mediates downstream signaling by binding to
the adaptor protein, mitochondrial antiviral-signaling protein (MAVS),
located on the outer membrane of the mitochondria, peroxisomes,
and on mitochondria-associated membrane (MAM) (Dixit et al., 2010;
Horner et al., 2011). This process results in establishment of a MAVS
signalosome that drives the activation of interferon regulatory factor 3
(IRF3) and NF-κB, leading to the expression of interferon (IFN)-β and
a variety of antiviral and immunomodulatory genes that confer antiviral
defense and that regulate immunity to infection (Loo and Gale, 2011).
Viral evasion and control of these processes supports chronic HCV infec-
tion in nearly 200 million people, thus marking RIG-I regulation of he-
patic defenses as a critical determinant impacting HCV infection and
immunity (Liu and Gale, 2010; Sumpter et al., 2005).
RIG-I has tandem amino-terminal caspase activation and recruit-
ment domains (CARDs) that mediate downstream signaling. RIG-I sig-
naling is governed through inhibitory intramolecular interactions of
the CARDswith its helicase domain and the carboxyl-terminal repressor
domain (RD) to hold RIG-I in an autorepressed state until its activation
mediated by binding to RNA PAMP ligand (Saito et al., 2007; Cui et al.,
2008; Jiang et al., 2011). RD engagement of 5′-ppp RNA induces
homotypic RD interaction with a partner RIG-I molecule bound to the
RNA ligand. Through this process the RD is shown to release the
autorepression of RIG-I, thereby facilitating RIG-I oligomerization and
ATP hydrolysis and ultimately leading to a signaling-on conformationthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Cui et al., 2008). This process then facilitates the formation of a RIG-I
translocon consisting of RIG-I/14-3-3ε/TRIM25 complex that mediates
the redistribution or “translocation” of RIG-I from cytosol to intracellu-
lar membrane compartments to bind MAVS through homotypic
CARD-CARD interactions (Liu et al., 2012). The E3 ubiquitin ligase
TRIM25 interacts with RIG-I at amino acid T55 and conjugates K63-
linked ubiquitin to RIG-I in a process that is required to release RIG-I
from autorepression (Gack et al., 2007). Introducing a T55I mutation
into RIG-I abrogates its interaction with TRIM25 and interrupts RIG-I
immune signaling, thus the cells become highly permissive to infection
by HCV and other RNA viruses (Sumpter et al., 2005; Gack et al., 2007).
RIG-I signaling is further regulated by Riplet-mediated K63-linked
polyubiquitination of the RIG-I RD, which also serves to release the
RIG-I CARDs from auto-inhibition for signaling activation (Oshiumi
et al., 2013), and by reversible phosphorylation of the CARDs that ﬁne-
tunes its activation (Wies et al., 2013). Following ligand-induced ATP
hydrolysis, RIG-I is placed in a signaling-on conformation (Guo et al.,
2011; Civril et al., 2011; Lu et al., 2011). Thus, in the current model of
RIG-I activation, the RNA PAMP ligand, the translocon, oligomeric as-
semblies containing RIG-I, and polyubiquitination are the prerequisites
for RIG-I to signal through downstream adaptorMAVS to initiate innate
immune responses.
The reversible acetylation of cytoplasmic protein complexes has
been shown to regulate major cellular processes, including signal trans-
duction and protein localization (Choudhary et al., 2009). Several his-
tone acetyl-transferases (HATs) and histone deacetylases (HDACs)
have been found to play critical roles in regulating type I interferon pro-
duction and response (Nusinzon and Horvath, 2006; Suh et al., 2010;
Zhu et al., 2011; Masumi, 2011). For example, a study identiﬁed that
HDAC6, a cytosolic HDAC, could enhance β-catenin nuclear transloca-
tion to facilitate IRF3 activation and type I IFN production during virus
infection (Zhu et al., 2011). Interestingly, a high-resolution mass spec-
trometry study identiﬁed lysine acetylation of RIG-I at residues K858
and K909 located within the RD (Choudhary et al., 2009). However,
whether lysine acetylation participates in RIG-I activation and innate
antiviral immunity is not known. Here, we deﬁne a role for the revers-
ible acetylation of RIG-I in modulating innate immune signaling during
RNA virus infection. We found that RIG-I is acetylated at adjacent sites
within the RD in resting cells, and this posttranslational modiﬁcation
prevents RIG-I oligomerization. During acute virus infection, RIG-I acet-
ylation is removed byHDAC6,whichdirectly binds to RIG-I. This process
facilitates PAMP RNA-induced RIG-I signaling activation. Our studies re-
veal that HDAC6 activity is crucial for RIG-I-dependent signaling to in-
nate antiviral immunity.2. Materials & Methods
2.1. Cells
Huh7 andHEK293 cells have been described (Saito et al., 2008). RIG-
I-knock-down cells were produced through transduction and selection
of cells with gene-speciﬁc pLKO.1-puro vector-based shRNA expression
cassettes (Sigma).2.2. Plasmids and Constructs
Flag-tagged RIG-I constructs have been described (Saito et al., 2007).
HA-tagged andMyc-tagged RIG-I expression constructs were generated
by cloning speciﬁc PCR products into pcDNA3.1 or pEF-Tak (Saito et al.,
2007). Acetyl-mimetic mutants of RIG-I were generated by using
QuikChange® Site-Directed Mutagenesis Kit (Stratagene). Flag-tagged
HDAC or SIRT constructs were obtained from Addgene (Addgene plas-
mid 13812, 13813, 13819, 13821, 13822, 13823, 13824, and 13825).2.3. RNA ChIP Assay
Huh7 cells were transfected with pEFBos-Flag-RIG-I and RIG-I
acetyl-mimetic mutants. Following 48 h post-transfection, in vitro tran-
scribed biotinyl-HCV PAMP RNAwas transfected into these cells for 1 h.
After two PBS washes, formaldehyde was added to the media to
crosslink the RNA and protein, and 0.125 M of glycine was added to
stop the reaction. The lysates were then used for anti-Flag immunopre-
cipitation and eluted by Flag peptide. The recovered products were di-
rectly dotted to nitrocellulose membrane for later immunoblotting to
detect Flag-tagged RIG-I by anti-Flag antibodies and biotinyl-PAMP
RNA by HRP-conjugated Strepavidin.
2.4. Virus Infection
For virus infection, 105 cells were cultured inwells of a 48-well plate
and were infected with HCV (strain HCV 2a/JFH1) in serum-free media
at 37 °C. One hour later, the cells were rinsed in PBS and incubated in
media containing 10% FBS. At the time of harvest, cells were washed
twice with PBS and ﬁxed in 3% Paraformadehyde:PBS solution. Cells
were immunostained with anti-HCV serum as described.
2.5. Immunoprecipitation
Cells were lysed in ice-cold RIPA buffer (50 mM Tris-Cl pH 7.5,
150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS) in the presence of Protease Inhibitor Cocktail (Roche) for 10 min.
Lysates were clariﬁed by centrifugation and incubated with 2 μg of anti-
bodies for 16 h followed by Protein A/G agarose for 1 h at 4 °C. The
immunocomplexes were washed 3 times with cold RIPA buffer and re-
suspended in 15 μl of 2× SDS sample buffer for SDS-PAGE. Commercial
antibodies used in this study were: Anti-FLAG monoclonal antibody,
Sigma-Aldrich Cat# P2983 RRID:AB_439685; anti-HA onoclonal anti-
body, Antibodies-Online.com - The Marketplace for Antibodies Cat#
ABIN289443 RRID:AB_10775823; anti-ubiquitin polyclonal antibody,
Antibodies-Online.com - The Marketplace for Antibodies Cat#
ABIN361830 RRID:AB_10789886; anti-HDAC6 polylconal antibody,
Fitzgerald Industries International Cat# 20R-1669 RRID:AB_11191264.
2.6. ATPase Assay
WT and mutant RIG-I were expressed and puriﬁed from Escherichia
coli. 10 nM of puriﬁed RIG-I protein was incubated with 125 nM of RNA
ligands, including 18-bp dsRNA, 14-bp dsRNA, 24-mer hairpin RNA and
5′-ppp hairpin RNA. The initial ATP concentrationwas 1mM, and spiked
with [γ-32P]ATP at 37 °C. A time course (0–30 min) of the ATPase reac-
tion was used to determine the rates of ATP hydrolysis.
2.7. Gel Shift Assay
[γ-32P] end-labeled 18-bp RNA was incubated with puriﬁed WT or
mutant RIG-I protein at vrious concentration from 0.2 pmol to
10 pmol in 20 μl reactions. The protein-RNA complex was then run in
a 6% Native PAGE followed by radioautography.
2.8. Luciferase Reporter Assay
Dual luciferase assays to measure Interferon β promoter activity
were conducted as described (Saito et al., 2008).
2.9. In Vivo Mouse Infections
C57BL/6 (WT) mice were purchased from Jackson Laboratories, Bar
Harbor, ME. HDAc6 deﬁcient mice were generously provided by Dr.
EduardoM. Sotomayor (H. LeeMofﬁtt Cancer Center andResearch Insti-
tute, Tampa, FL 33612) (Cheng et al., 2014). Allmicewere genotyped for
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pathogen-free conditions in the animal facility at the University of
Washington. All experiments were performed in accordance with the
University of Washington Institutional Animal Care and Use Committee
guidelines. Age-matched 7–8 week old mice were inoculated subcuta-
neously in the rear footpad with 100 PFU of WNV TX-02 strain (Keller
et al., 2006) in a 20 μl inoculum diluted in phosphate buffered saline
(PBS) supplemented with 1% heat-inactivated fetal bovine serum.
Mice were monitored daily for morbidity and mortality. For clinical
scoring, infected mice were monitored daily for signs of hind limb dys-
function and paresis. Micewere scored using the following scale of 1–6:
1, rufﬂed fur/lethargy, no paresis; 2, very mild to mild paresis; 3, frank
paresis involving at least one hind limb and/or conjunctivitis; 4, severe
paresis; 5, true paresis; 6, moribund. Each experiment included cohorts
of 10 each WT and HDAC6−/− mice either mock-infected or infected
with WNV. Three experiments were performed. Statistical signiﬁcance
for weight and clinical scores were determined using the Holm-Sidak
method of multiple t-tests, with alpha = 5.000%. *p value b 0.005.
2.10. Statistical Analysis
Data were compared using Student's t-test.
3. Results
3.1. RIG-I is Acetylated in Resting Cells but Deacetylated During Acute Virus
Infection
To determine if RIG-I is acetylated in resting cells, endogenous, full-
length RIG-I was recovered by immunoprecipitation (IP) from HEK293
cells thatwere treatedwith increasing doses of a pan-deacetylase inhib-
itor, Trichostatin A (TSA). The recovered RIG-I was assessed for acetyla-
tion by immunoblot analysis using an anti-acetyl-lysine antibody. We
found that RIG-I was basally acetylated in resting, non-infected cells
and that increasing doses of TSA resulted in increased levels of acetyl-
RIG-I (Fig. 1A). To identify the potential sites of lysine acetylation of
RIG-I, we ectopically expressed Flag-tagged RIG-I and RIG-I truncation
mutants containing C-terminal domain of RIG-I (C-RIG) or the green
ﬂuorescence protein fused to the RIG-I RD (GFP-RD) (Fig. 1B) and
used immunoblot assay to probe for levels of acetyl-lysine on RIG-I fol-
lowing immunoprecipitation of each construct. These experiments
were conducted in the presence or absence of infection with Sendai
virus (SenV), an RNA virus that triggers RLR signaling and accurately
models hepatitis C virus (HCV) activation of RIG-I (Saito et al., 2008).
Full-length RIG-I, C-RIG, and GFP-RD were acetylated in resting, non-
infected cells but during SenV infection the acetylation levels decreased
(Fig. 1C). Notably, a construct encoding the Flag-tagged N-terminal
CARDs of RIG-I (N-RIG) was not acetylated (Fig. S1A). Taken together,
these results localize acetylation to the RIG-I RD inclusive of K858 and
K909. To assess whether K858 and K909 were indeed the sites for
RIG-I acetylation, Flag-tagged GFP-RD K858-909R mutant (GFP-RD-
RR) was generated by site-direct mutagenesis. We then assessed the
level of acetyl-lysine within the GFP-RD-RR mutant when expressed
in 293 cells. GFP-RD-RR protein was recovered by anti-FLAG IP and sub-
jected to anti-acetyl-lysine immunoblot assay in parallel analyses with
IP products recovered from cells expressing C-RIG, GFP-RD, RIG-I 1-
734, or vector alone (pEFBos). We found that while both C-RIG and
GFP-RD were acetylated in resting cells, neither RIG-I 1-734 nor GFP-
RD-RR was acetylated (Fig. 1D). Moreover, full-length RIG-I mutants
containing individual pointmutation of K858R or K909R each exhibited
reduced acetylation levels compared to RIG-IWT (Fig. 1E). These results
verify that residues K858 and K909 of RIG-I are acetylation targets in
resting cells.
To assess how the acetylation of RIG-I regulates its signaling activi-
ties, we introduced acetyl-mimetic mutations into a RIG-I expression
construct by site-directed mutagenesis, whereby the lysine at residuesK858 and K909 were mutated to glutamine to mimic the steric and
charge characteristics of acetylated lysine (Xiong and Guan, 2012).
The resultant K858Q or K909Q single-mutant or the K858-909Q double
mutant in comparison toWT RIG-I were assessed for their ability to sig-
nal IFN-β promoter activation in response to SenV infection. For these
experiments RIG-I knockdown Huh7 cells that stably express an
shRNA targeting RIG-I were reconstituted with either WT or mutant
RIG-I constructs in the presence of an IFN-β-luciferase reporter con-
struct, and either mock-infected or infected with SenV. As compared
to WT RIG-I, cells expressing any of the three acetyl-mimetic mutants
(K858Q, K909Q, and K858-909Q) of RIG-I were signiﬁcantly impaired
in their ability to signal IFN-β promoter activation in response to SenV
infection (Fig. 1F).Wepreviously found that RIG-I redistributes tomem-
brane fractions in response to virus infection, and this translocation is a
measure of RIG-I signaling activationwherein the RIG-I translocon facil-
itates RIG-I binding to MAVS (Liu et al., 2012). We evaluated whether
acetylation played a role in regulating the relocalization process by
comparing WT RIG-I and RIG-I acetyl-mimetic mutants for their ability
to redistribute from the cytosol to membrane fractions in response to
SenV infection. As a control we included a RIG-I K888-907A mutant
that cannot bind PAMP RNA and therefore precludes the formation of
the RIG-I translocon (Liu et al., 2012). In cell fractionation studies, we
found that a portion of WT RIG-I redistributed to the membrane
(M) fraction that also contains the mitochondria associated membra-
nous protein mitofusin 2 (MFN2) in response to SenV infection, as ex-
pected (Fig. 1G). In contrast, the RIG-I K858-909Q and the RIG-I K888-
907A mutants remained in the cytosolic (C) fraction along with control
protein tubulin. Neither mutant could be detected in the membrane
fractions regardless of whether the cells were infected with SenV, simi-
lar to RIG-I in resting cells. Consistent with these observations, RIG-I
K858-909Q could not undergo virus-induced interaction with MAVS
but WT RIG-I formed a complex with MAVS upon SenV infection (Fig.
S1B). These results reveal RIG-I to be acetylated within the RD at lysine
residues K858 and K909 wherein acetylation at these residues restricts
RIG-I translocation to intracellular membranes for MAVS interaction in
response to virus infection.
3.2. Acetylation Controls RIG-I Oligomer Formation
To deﬁne themolecular mechanism by which acetylation of RIG-I at
K858 andK909 restricts RIG-I activation,we further assessed the acetyl-
mimetic RIG-I mutants for their ability to bind PAMP RNA, to become
polyubiquitinated, and to oligomerize, all of which are step-wise pro-
cesses essential for RIG-I signaling activation (Chan and Gack, 2015).
In particular, K858 of RIG-I has been implicated in participating in bind-
ing to RNA ligand cooperatively with K861 (Shigemoto et al., 2009).We
ﬁrst evaluated WT RIG-I and the acetyl-mimetic mutants, RIG-I K858Q,
RIG-I K909Q, and RIG-I K858-909Q for their ability to bind to synthetic
5′ppp-containing ssRNA PAMP ligands. As a further control, we includ-
ed for comparison a RNA-binding defective RIG-I K858-861A mutant
(Shigemoto et al., 2009). We transfected in vitro transcribed biotinylat-
ed HCV 5′-ppp poly-U/UC PAMP RNA (Schnell et al., 2012; Saito et al.,
2008) into Huh7 cells that express Flag-tagged WT RIG-I, RIG-I acetyl-
mimetic mutant, or RIG-I K858-861A, and assessed the level of PAMP
RNA thatwas recovered in a complexwith FlagRIG-I by IP and immuno-
blot analysis. PAMP RNA that is recovered as part of the RIG-I complex
was detected using alkaline phosphatase-conjugated streptavidin. We
found that each acetyl-mimetic mutant of RIG-I (K858Q, K909Q, and
K858-909Q) retained PAMP RNA-binding activity similar to WT RIG-I
(Fig. 2A). In contrast, RNA binding activity of the RIG-I K858-861A mu-
tant was attenuated in comparison to WT RIG-I. We further evaluated
WT and mutant RIG-I for their ability to bind to a dsRNA PAMP ligand
in electrophoretic mobility shift assays (EMSA) using puriﬁed recombi-
nant proteins. The acetyl-mimetic mutants of RIG-I all retained the abil-
ity to bind to an 18-bp dsRNA PAMP ligand in a concentration-
dependent manner, which is measured by the decrease in signal from
Fig. 1. RIG-I is acetylated in resting cells. (a) Endogenous RIG-I was immunoprecipitated (IP) from mock or TSA treated cell lystate. Acetyl-RIG-I level was detected by anti-acetyl-lysine
antibody. (b) Illustration of RIG-Imutants used in (c) to (g). (c) Ectopically expressed Flag-tagged RIG-I andmutants were recovered by IP frommock or SenV-infected cell lystate. Acetyl-
lysine levelswere detected by immunoblotting. Relative intensities of acetyl-RIG-I to total Flag-RIG-I wasmeasured and calculated by Image J software and expressed as a value relative to
the corresponding uninfected control. (d) Ectopically expressed Flag-tagged RIG-I andmutantswere recovered by IP and analyzed for acetylation levels by immunoblot (blot) assay. GFP-
RD-RR referred to Flag-tagged GFP-fused RIG-I RDwith K858-909Rmutations. (e) Ectopically expressed Flag-tagged RIG-I andmutants were recovered by IP frommock or SenV-infected
cell lystate. Acetyl-lysine levels were detected by immunoblot assay. (f) SenV-induced IFN-β promoter induction in RIG-I knock-down Huh7 cells complemented with WT RIG-I or RIG-I
acetyl-mimeticmutants. (g)Membrane (M) localization of RIG-I to theMAMfroma resting, cyosolic (C) state during SenV infection. RIG-I acetyl-mimeticmutantswere not detected in the
membrane fractions, whereas WT RIG-I was redistributed to the MAM as marked by mitofusin 2, a MAM protein during SenV infection. Tubulin marks the cytosolic fraction.
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of slower migrating bands of RIG-I:RNA complexes (Figs. 2B and S2A).
Among the mutants, RIG-I K858-909Q exhibited comparably reduced
dsRNA-binding efﬁciency in this assay wherein lower levels of the 1:1RIG-I:dsRNA complex were detected with the K858-909Qmutant com-
pared toWT, and this mutant formed little, if any, of the higher 2:1 RIG-
I:dsRNA complexes (Fig. 2B). More importantly, all three RIG-I acetyl-
mimetic mutants were attenuated in their ability to oligomerize in the
Fig. 2. Oligomerization difﬁciency of RIG-I acetyl-mimetic mutants. (a) in vitro transcribed biotinylated-PAMP RNA from HCV 3′UTR was transfected into cells expressing the indicated
Flag-tagged RIG-I mutants. After crosslinking, PAMP RNA/RIG-I complexes were recovered by anti-Flag IP and blotted onto nitracellulose membrane. RNA is visualized using
Streptavidin-HRP. Relative RNA binding activities were quantiﬁed using Image J software, and expressed as a value relative to the corresponding WT control. (b) Representative gel-
shift assays for WT and RIG-I mutants in the presence of 18-bp dsRNA. The oligomer formation efﬁciency of RIG-I-RNA (2:1) complex by band intensities was quantiﬁed and plotted.
(c) Relative RNA-stimulated ATP hydrolysis of WT RIG-I and three RIG-I mutants. Data were normalized to WT RIG-I and shown as the relative level ATPase rate. Error bars represent
the standard deviation of triplicate measurements. (d) Impaired oligomerization of RIG-I acetyl-mimetic mutants during SenV infection. Flag-tagged wt RIG-I and HA-tagged RIG-I
acetyl-mimetic mutants were co-transfected into HEK293 cells. After SenV infection, cell extracts were subjected to IP by anti-Flag antibody. RIG-I oligomerization activities were
shown by the levels of co-IP HA-tagged RIG-I. Arrows indicate Flag-RIG-I oligomers. (e) RIG-I translocon formation. HEK293 cells expressing Flag-tagged WT or mutant RIG-I were co-
expressed with Myc-14-3-3ε and cells were infected with 100 HAU SenV for 16 h followed by anti-Flag IP of cell extracts. The products were analyzed by immunoblot with anti-
TRIM25 antibody or anti-Myc antibody.
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RIG-I:dsRNA bands in comparison to WT RIG-I, with the K858-909Q
mutant having almost a complete loss of the 2:1 oligomer product
(Fig. 2B). These results suggest that although they retain the ability to
recognize and bind PAMP RNA, acetyl-mimetic RIG-I is restricted in its
ability for forming RNA-induced oligomers. Thus, PAMP RNA-induced
oligomerization of RIG-I is regulated by acetylation of RIG-I at K858
and K909 sites.
Binding to PAMP RNA induces RIG-I hydrolysis of ATP to facilitate
the conformational change that places RIG-I into a signaling-on confor-
mation that promotes oligomerization (Chan and Gack, 2015). To di-
rectly assess how RIG-I oligomerization is regulated by acetylation at
K858 and K909, and how this process might impact RIG-I interactions
with TRIM25 and 14-3-3ε to assemble the translocon, we conducted
ATPase and co-IP studies to assess the state of RIG-I activation. We
assessed ATPase activity of RIG-I WT and RIG-I K858-909Q acetyl mi-
metic mutant induced by different PAMP RNA ligand including 18-bp
or 14-bp dsRNA, and 24-mer hairpin RNAwith or without 5′-ppp. Com-
pared to WT RIG-I, the ATPase activity of RIG-I K858-909Q induced by
each RNA ligandwas attenuated (Fig. 2C), indicating that RD acetylation
of RIG-I impedes its ability to hydrolyze ATP and thus may impair olig-
omerization of RIG-I. We next co-expressed Flag-tagged RIG-I WT and
acetyl-mimetic mutants of HA-tagged RIG-I, and evaluated their capac-
ity in forming virus-induced interaction by co-IP assays. SenV infection
induced robust interaction of HA-RIG-IWTwith FLAG-RIG-I WT, but in-
teraction of RIG-IWTwith eitherHA-RIG-I K858Q, K909Qor K858-909Q
mutant failed to occur in response to SenV infection (Fig. 2D). We then
assessed virus-induced complex formation of RIG-I with TRIM25 and
14-3-3ε, the essential components of the RIG-I translocon (Liu et al.,
2012). For these analyses we assessed the partner binding activity of
the RIG-I K858-909Q double mutant compared to RIG-I WT and a RIG-
I K888-907A doublemutant control that is known to completely abolish
RNA-binding activity (Wang et al., 2010).We found that the RIG-I K858-
909Q acetyl mimetic double mutant was still able to form a virus-
induced complex to interact with both 14-3-3ε and TRIM25 during
SenV infection at a similar level to RIG-I WT (Fig. 2E). However, the
RIG-I K888-907A mutant was defective in its ability to undergo virus-
induced interaction with TRIM25 and 14-3-3ε, thus deﬁning PAMP
RNA binding as a critical step in promoting RIG-I translocon formation.
We further assessed the extent of K63-linked RIG-I ubiquitination as
mediated by TRIM25 (Gack et al., 2007) and found that the
ubiquitination levels of the RIG-I WT and K858-909Q acetyl mimetic
mutant were similar following induction by SenV infection (Fig. S2B).
Taken together, these data reveal that K858-909 acetylation restricts
RNA-induced RIG-I ATPase activity and oligomer formation but not in-
duction of translocon formation nor ubiquitination of RIG-I, and that
this control occurs at a step followingRIG-I binding to PAMPRNA ligand.
Todetermine how acetylationmight serve to control RIG-I from spu-
rious activation in non-infected, resting cells, we evaluated RIG-I oligo-
merization and activation of innate immune signaling among acetyl
mimetic RIG-I mutants designed to disrupt interdomain interactions
that otherwise regulate RIG-I signaling. In particular, we compared the
signaling actions of WT and RIG-I K858-909Q to RIG-I F539A. In resting
cells RIG-I is maintained in an autorepressed state through the RD
which imparts helicase (Hel2i) domain interactions of F539 with the
CARDs wherein F539A mutation of RIG-I releases this autorepressionFig. 3. RIG-I deacetylation by the cytoplasmic deacetylase HDAC6 during viral infection. (a) and
mock-infected or SenV-infected Huh7 cells that were treatedwith DMSO control or HDAC inhib
Bufexamac (Bufex). (b) Huh7 cells were transfected with vector lone or the constitutively acti
Bufexamac. 12 h later the cells were harvested and assessed for IFN-β-luciferase activity. *:
tagged RIG-I were co-transfected into HEK293 cells. Cells were mock or SenV infected and ex
anti-Flag or anti-Myc immunoblot analysis. (d) Endogenous RIG-I and HDAC6 form virus-indu
antibody. Recovered proteins were identiﬁed by immunoblot assay for RIG-I, HDAC6 and HDA
DMSO (control) or Tubastatin A treatment. 16 h later the cells were co-stained with DAPI to
antibody for immunostain analysis of IRF3 subcellular distribution. (f) WT and IFNAR KO MEF
Tubastatin A or Tubacin, during mock infection or SenV infection. 16 h later the cells were harresulting in a level of constitutive RIG-I signaling (Kowalinski et al.,
2011). We expressed WT RIG-I, RIG-I F539A, or the acetyl mimics of
RIG-I, in Huh7 RIG-I knockdown cells that lacked expression of endoge-
nous RIG-I. We found that RIG-I F539A exhibited a level of constitutive
signaling activity but this constitutive activity was reduced in the con-
text of the K858-909Q acetyl-mimetic mutations (RIG-I AQQ triple mu-
tant) (Fig. S2C). Thus, evenwhen RIG-I is placed in a “signaling-on” state
through disruption of inhibitory domain interactions, as is the case of
the F539A mutant, acetyl mimetic mutation of K858-909Q restricts
RIG-I signaling. To test how these acetyl-mutations impacted RIG-I
protein-protein interactions in resting cells we evaluated the interac-
tion of HA-RIG-I WT with Flag-tagged RIG-I WT, RIG-I F539A, and RIG-
I AQQ mutants following co-expression in Huh7 RIG-I knockdown
cells. Cells were harvested at 24 h post-transfection, and proteins
were co-immunoprecipitated with anti-Flag antibody then subjected
to anti-HA immunoblot analysis. As expected, in noninfected, resting
cells, WT RIG-I was present only as a monomer and subsequently
formed a RIG-I complex upon SenV infection. However, RIG-I F539A
formed a constitutive complexwith RIG-IWT, consistentwith its consti-
tutive signaling activity (Fig. S2D). In contrast, this constitutive RIG-I
binding activity of the F539A mutant exhibited a N4-fold reduction
when this mutation was placed in context of the RIG-I AQQ triple mu-
tant. Taken together, these observations show that K858-909Q muta-
tion regulates intramolecular interactions of RIG-I to control its
signaling activity. These results imply that acetylation governs RIG-I
oligomerization actions to thus prevent aberrant activation in the ab-
sence of virus infection. Deacetylation of RIG-I is therefore required to
facilitate the RIG-I oligomerization/activation process.3.3. HDAC6 is the RIG-I Deacetylase
To identify the speciﬁc deacetylase that mediates RIG-I
deacetylation, we examined RIG-I signaling to the IFN-β promoter in
cells treated with HDAC inhibitors. HEK293 cells were treated with a
pan-HDAC inhibitor (Trichostatin A, TSA), nuclear HDAC inhibitor
(valproate, VPA), or cytoplasmic HDAC inhibitor (Bufexamac)
(Bantscheff et al., 2011) followed by SenV infection to induce RIG-I sig-
naling and activation an IFN-β promoter luciferase construct. TSA treat-
ment has been shown previously to block IFN-β production (Nusinzon
and Horvath, 2006). While both Bufexamac and TSA treatment blocked
IFN-β promoter induction by SenV in a dose-dependent manner, treat-
ment of cells with VPA did not decrease IFN-β promoter induction as
compared to nontreated cells (Fig. 3A). TSA also blocked IFN-β promot-
er induction by the constitutively active N-RIG construct but important-
ly, Bufexamac treatment did not block IFN-β promoter induction by N-
RIG. Thus, RIG-I lacking its C-terminal region containing the acetylation
sites is not subject to regulation by the cytoplasmic HDACs (Fig. 3B). To
identify the HDACs that target RIG-I, we co-expressedMyc-tagged RIG-I
and Flag-tagged cytoplasmic HDACs in HEK293 cells and subjected ly-
sates to a co-IP analysis. Both HDAC3 and HDAC6 were recovered with
RIG-I in anti-Flag IP reactions, regardless of virus infection (Fig. 3C).
We therefore assessed endogenous RIG-I interaction with endogenous
HDAC6 or HDAC3. Intriguingly, we found that endogenous RIG-I and
HDAC6 formed a virus-inducible complex within three hours after
SenV infection but endogenous HDAC3 did not interact with RIG-I(b) RIG-I signaling to the IFN-β promoter was measured by promoter-luciferase assay in
itor. (a) cells were treatedwith increasing dose of Tricostatin A (TSA), Valproate (VPA), or
ve N-RIG mutant and cultured in the presence of treatment with DMSO (control), TSA, or
p value b 0.05. (c) Screening of RIG-I interacting HDACs. Flag-tagged HDACs and Myc-
tracts prepared 16 h later. Proteins were recovered by anti-Myc co-IP and identiﬁed by
cible complexes. Mock or SenV-infected Huh7 cell lysates were used for IP by anti-RIG-I
C 3. (e) Huh7 cells were mock infected or infected with SenV for 16 h in the presence of
detect the nucleus and anti-IRF3 antibody followed by anti-rabbit ﬂourescein secondary
s were treated with DMSO control or with increasing levels of HDAC6 speciﬁc inhibitor,
vested and the level of IFIT2 mRNA was quantiﬁed by RT-qPCR assay. *: p value b 0.05.
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ing acute virus infection.
To assess the role of HDAC6 as a RIG-I deacetylase, we examined the
level of acetyl RIG-I in cells treated with increasing amounts of the
HDAC6-speciﬁc inhibitor, Tubastatin A (Haggarty et al., 2003).
Tubastatin A treatment resulted in increased abundance of acetyl-RIG-
I (Fig. S3). We therefore tested whether or not Tubastatin A couldsuppress RIG-I-dependent signaling of IRF3 activation in Huh7 cells.
Cells were pretreated with Tubastatin A for 2 h and then infected with
SenV for 16 h to induce RIG-I-dependent IRF3 activation, which can be
measured by assessing IRF3 nuclear translocation. SenV infection in-
duced the nuclear accumulation of IRF3 but this was blocked by treat-
ment of cells with Tubastatin A (Fig. 3E). To determine if HDAC6 was
required for induction of direct IRF3-target genes, we assessed the
202 H.M. Liu et al. / EBioMedicine 9 (2016) 195–206expression of interferon-induced proteinwith tetratricopeptide repeats
(IFIT)2 gene inWTmouse embryo ﬁbroblasts (MEFs) and in MEFs from
mice with a targeted deletion in the type-1 interferon receptor (IFNAR
KO). Cells were treated with HDAC6 speciﬁc inhibitors, Tubastatin A or
Tubacin, infected with SenV, and harvested for RT-qPCR assay to mea-
sure IFIT2 mRNA level (Fig. 3F). IFIT gene expression can be induced
after virus infection directly upon IRF3 activation aswell as upon IFN sig-
naling because of the presence of both IRF3 and ISGF3 binding sites in the
promoter (Fensterl and Sen, 2011; Dafﬁs et al., 2007). Virus-induced
IFIT2 mRNA levels in both WT and IFNAR−/−MEFs were suppressed in
cells treated with Tubastatin A or Tubacin (Fig. 3F, left and right panels
respectively). Similar results but with a higher level of SenV-induced
IFIT2 mRNA expression was observed in WT MEFs, likely reﬂecting IFN
receptor-dependent signaling ampliﬁcation. It is notable that HDAC6
has been reported to act as a coactivator of the IFN-β promoter-
enhancer wherein HDAC6 was shown to operate upstream of IRF3
(Nusinzon and Horvath, 2006). Taken together, these observations indi-
cate that HDAC6 imparts control of RIG-I-dependent signaling of IRF3 ac-
tivation and target gene expression. Thus, HDAC is the RIG-I deacetylase.
3.4. HDAC6 is Essential for RIG-I-dependent Antiviral Innate Immunity
To determine the role of HDAC6 in RIG-I signaling of innate antiviral
immunity, we examined innate immune signaling and virus infection in
the context of HDAC knockdown in human cells. Huh7 cells were
transfected with non-targeting (NT) siRNA, or with siRNA targeting
HDAC3 (control) or HDAC6, followed by SenV infection or transfected
with N-RIG expression construct to trigger RIG-I signaling (Fig. 4A and
B). Knockdown of HDAC6 but not HDAC3 resulted in reduced IFN-β pro-
moter induction upon SenV infection, as compared to NT siRNA
transfected control cells (Fig. 4A). However, ectopic expression of N-
RIG in NT control cells or HDAC3- or HDAC6- knockdown cells induced
IFN-β promoter activity (Fig. 4A), indicating that HDAC6 requires the
RIG-I C-terminal region to negatively regulate RIG-I signaling. We also
assessed whether ectopic HDAC6 expression could enhance RIG-I sig-
naling. HEK293 cells were co-transfected with vector, HDAC3, or
HDAC6 in combination with an over-expression construct encoding
RIG-I WT or the RIG-I K858-909Q double mutant. As shown in Fig. 4C,
HDAC6 but not HDAC3 enhanced signaling by RIG-I WT after SenV in-
fection but failed to enhance signaling by RIG-I K858-909Q. Further-
more, ectopic HDAC6 supported more rapid RIG-I signaling after SenV
infection (Fig. 4D) but an HDAC6 active site mutant, HDAC6-DC, lacking
acetyl-transferase activity, did not enhance RIG-I signaling (Fig. S4A).
We also conducted parallel studies to assessMDA5 signaling in the pres-
ence of ectopic HDAC6 expression or in HDAC6 knockdown cells during
mock-infection or infection with encephalomyocarditis virus (EMCV), a
knownMDA5-speciﬁc agonist (Loo andGale, 2011). EMCV-induced sig-
naling ofMDA5 to the IFN-β promoterwas neither altered byHDAC6 in-
hibitor treatment nor HDAC6 knockdown (data not shown), indicating
that HDAC6 speciﬁcally regulates RIG-I and not MDA5. We therefore
assessed HDAC6 interaction with RIG-I to identify the domain of
HDAC6 that mediates binding to RIG-I. We found that binding to RIG-I
occurred exclusive of theN-terminal 80 a.a. of HDAC6 and independent-
ly of the ubiquitin-binding domain (BUZ domain; Fig. S4B), suggesting
that HDAC6/RIG-I interaction is mediated by the HDAC6 C-terminal re-
gion that encodes the catalytic domain (Fig. S4C).
To determine if HDAC6 was required to protect the cells from RNA
virus infection,we further evaluated viral RNA level or replication of dis-
tinct RNA viruses including SenV (a paramyxovirus), HCV (a
hepacivirus), and West Nile Virus (WNV, a ﬂavivirus) infection.
Tubastatin A or Tubacin treatment of Huh7 cells resulted in increased
SenV RNA levels after 16 h of infection compared to nontreated cells
(Fig. 4E). Moreover, transfection of increasing amounts of HDAC6-
speciﬁc siRNA but not HDAC3-speciﬁc siRNA in Huh7 cells signiﬁcantly
enhanced permissiveness for HCV (JFH-1) infection as compared to NT
control Huh7 cells (Fig. 4F), with the level of enhancementapproximating that observed in cells with 14-3-3ε knockdown that ab-
rogates the RIG-I translocon and concomitant RIG-I signaling (Liu et al.,
2012). Notably, the reduction of IFIT2mRNA expression we observed in
our studies (see Fig. 3F), corresponds with the loss of immune signaling
and enhanced permissiveness to virus infection imposed by loss of
HDAC6 expression level or inhibition of its acetyl-transferase activity
(Figs. 3F and 4E). We further evaluated WNV TX-02 infection of WT or
HDAC KO mice. During early WNV infection, RIG-I serves a dominant
role for the acute induction of innate immunity and protection against
WNV infection in vivo; however,MDA5 has a nonredundant role in con-
tributing to retain active immunity and protection against WNV infec-
tion at later times following RIG-I signaling (Errett et al., 2013; Suthar
et al., 2010). Thus, we focused our assessment of the clinical scores
and weight loss in mice infected with WNV TX-02 during the ﬁrst
week of infection. Clinical symptoms were monitored daily during the
course of infection to observe the disease occurrence and
neurovirulence. BothWTandHDAC6KOmicewere susceptible to infec-
tion, with HDAC6 KO mice showing increased and more rapid onset of
disease during early/acute infection, consistent with the kinetics of
RIG-I-dependent signaling of innate immunity in acute WNV infection
(Errett et al., 2013). When compared with the WT controls, HDAC6 KO
mice displayed earlier symptoms 2 to 3 days post-infection (Fig. 4G)
that associated with early weight loss (Fig. 4G). These results demon-
strate thepositive role of HDAC6 in RIG-I-dependent activation of innate
immunity to protect against RNA virus infection.
4. Discussion
RIG-I is a major sensor of RNA virus infection. Among the RLRs,
MDA5 has also been shown to act as an essential PRR for recognition
of speciﬁc viruses such as picornaviruses, and to act cooperatively
with RIG-I in recognition of ﬂaviviruses and reoviruses (Loo et al.,
2008). In contrast, LGP2, the third member of the RLR family, might
serve as a co-factor or negative regulator of RLR signaling (Saito et al.,
2007; Komuro and Horvath, 2006; Satoh et al., 2010). In terms of RIG-
I, multiple steps are required for its activation, including RNA-binding
dependent conformational change, polyubiquitination of the N-
terminus CARD and the C-terminus RD, phosphorylation, formation of
the RIG-I/14-3-3ε/TRIM25 translocon, ATPase hydrolysis, and oligomer-
ization (Liu et al., 2012; Saito et al., 2007; Cui et al., 2008; Oshiumi et al.,
2013; Gack et al., 2007; Maharaj et al., 2012; Wies et al., 2013).
Homotypic complex formation of signaling molecules is a feature of in-
nate immune signaling activationwherein complex formation is subject
to regulation by post-translational protein modiﬁcations (Takashima
et al., 2015; Gay et al., 2014; Blander, 2014). Our results show that
RIG-I speciﬁc deacetylation at residues K858 and K909 by HDAC6 is re-
quired for its oligomerization that is essential for activation in response
to virus infection and PAMP RNA transfection, and that HDAC6 directly
regulates the IRF3-dependent IFN-β gene expression by reversing RIG-I
acetylation. We found that the K858Q and K909Q acetyl-mimetic mu-
tants of RIG-I showed moderate RNA binding activities but reduced
homo-oligomerization and ATPase activities. That K858-909Q mutant
RIG-I cannot signal downstreamgene inductionwhile failing tomediate
virus-induced oligomer formation suggests that oligomeric RIG-I is the
active unit that engagesMAVS for innate immune activation. Our results
suggest a model in which in resting cells, RIG-I is acetylated within the
RD at K858 and K909 to regulate intramolecular interactions between
the RD-Heli2 domains and hold RIG-I in a signaling-off conformation
for preventing PAMP RNA ligand-independent homo-oligomerization
and signaling activation. Binding to PAMP ligand RNA promotes a con-
formation change (Saito et al., 2007) that permits HDAC6 interaction
for deacetylation of the RD (Fig. 5). This process then releases RIG-I
autorepression and allows RIG-I to undergo ATP hydrolysis and form
signaling-active homo-oligomers within the RIG-I translocon that facil-
itates MAM targeting and interaction with MAVS for innate immune
signaling (Liu et al., 2012; Bhatia et al., 2011). During viral infection,
Fig. 4. HDAC6 deacetylase activity is required for RIG-I signaling induction. (a) Huh7 cells were transfected with nontargeting siRNA control (NT) or siRNA speciﬁc for knockdown of
HDAC3 or HDAC6. Cells were then infected with SenV or transfected with vector or N-RIG to induce signaling in the presence of the IFN-β-luciferase promoter construct. IFN-β
promoter activity was measured 16 h later. (b) HDAC6 and HDAC3 protein levels from siRNA treated cells in A. (c) WT or mutant RIG-I was ectopically expressed with vector control,
HDAC3 or HDAC6 in combination in the presence of the IFN-β-luciferase promoter in Huh7 cells. Cells were mock infected or infected with SenV and harvested for assessment of IFN-
β promoter activity 16 h later. (d) WT RIG-I was ectopically expressed with vector control or HDAC6 in combination in the presence of the IFN-β-luciferase promoter in Huh7 cells.
Cells were mock infected or infected with SenV and harvested at the indicated time for assessment of IFN-β promoter activity. (e) Huh7 cells were treated with DMSo control,
Tubastatin A or Tubacin and mock infected or infected with SenV. Cells were harvested and viral RNA measured by RT-qPCR assay 24 h later. (f) Huh7 cells were treated with NT
siRNA or increasing levels of siRNA for knockdown of HDAC3 or HDAC6. Cells were infected with HCV. Infectious virus in supernatant was determined at 48 h post-infection by viral
focus forming unit assay. *: p value b 0.05; **: p value b 0.01. (G) WT and HDAC KO mice were challenged with WNV and monitored for clinical scores and weight loss. Statistical
signiﬁcance was determined using the Holm-Sidak method of multiple t-tests, with alpha = 5.000%. *: p value b 0.05.
203H.M. Liu et al. / EBioMedicine 9 (2016) 195–206RIG-I expression levels are increased in response to IRF3 activation and
IFN signaling, such that newly-synthesized RIG-I may have a lower
threshold for activation due to having lower acetylation levels. Thus,during virus infection the deacetylation of RIG-I by HDAC6 represents
a critical step in the process of innate immune activation to relieve
autorepression.
Fig. 5.Model of HDAC6-depende t RIG-I activation. Details are described in the text.
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amino acid, has been shown to be involved in regulation of protein in-
teractions, DNA binding, RNA bindings, and many other various protein
functions (Choudhary et al., 2009; Shakespear et al., 2011; Schwartz
et al., 2010). EighteenHDACgenes have been identiﬁed and are grouped
into four classes based on their sequence homology; among these
HDACs, HDAC6 and HDAC10 (class IIb HDACs) are distributed primarily
in the cytoplasm, and other classes of HDACs are distributed in the nu-
cleus (class I and IV), in the mitochondria (class III), or shuttling in be-
tween the nucleus and cytoplasm (class IIa) (reviewed in (Shakespear
et al., 2011)). Besides the important functions of HDACs in histonemod-
iﬁcation and regulation of gene expression, emerging roles of HDACs in
regulating inﬂammation and innate immune response are now being
revealed (Klampfer et al., 2004; Nusinzon and Horvath, 2006;
Vlasakova et al., 2007). For example, HDAC1, HDAC2, HDAC3, and
HDAC8 repress the transcription factor NF-κB and MTA-1 (reviewed in
(Shakespear et al., 2011)). HDAC6, however, was reported to promote
IFN production in an IRF3-dependent manner (Nusinzon and Horvath,
2006), in which we now assign RIG-I as an HDAC6 target that facilitates
IRF3 activation and IFN production. In our study, IRF3 nuclear transloca-
tion during SenV infection was blocked by treatment of cells with the
HDAC6 speciﬁc inhibitors Tucastatin A and Tubacin, consistent with re-
cent reports (Chattopadhyay et al., 2013). However, these HDAC6-
associated effects on IRF3 were noted to be indirect, and our data now
indicate that the regulatory events byHDAC6 occur upstreamof IRF3 ac-
tivation at the level of RIG-I signaling activation. HDAC6-inhibition en-
hanced the susceptibility of cells to both HCV and SenV infections. In
fact, some viruses have developed strategies to control host immune re-
sponse by modulating the activities of HDACs to disregulate the
transactivator functions of IRFs, such as human papillomavirus E7 viral
protein and respiratory syncytial virus-inducing cellular BCL-3
(Jamaluddin et al., 2005; Park et al., 2000). HDAC6 was also reported
to be targeted and cleaved by inﬂuenza A virus-induced Caspase-3
(Husain and Harrod, 2009) and to regulate HIV-1 infection by reversing
α-tubulin acetylation and therefore preventing HIV-1 envelope-
dependent infection (Valenzuela-Fernandez et al., 2005). In addition, a
recent report showed that overexpression of HDAC6 enhances resis-
tance to adenovirus and H5N1 Inﬂuenza virus infections in murine em-
bryonic stem cells, suggesting an important role of HDAC6 in anti-viral
activities in both RIG-I dependent and independent actions (Wang
et al., 2015). Of note is that while this current report was in revision,Choi, et al. reported their study showing that HDAC6 serves to
deacetylate lysine 909 of RIG-I to facilitate innate immune induction
in response to RNA virus infection (Choi et al., 2016). Our results vali-
date and extend these observations to deﬁne both K858 and K909 as
acetyl-lysine residues targeted by HDAC6 to regulate RIG-I function.
HDAC6 contains two tandem catalytic domains, an ubiquitin-
binding domain (BUZ), and a dynein-binding domain (reviewed in
(Boyault et al., 2007)). Besides α-tubulin, which is the major substrate
of HDAC6,β-catenin, peroxiredoxin, Hsp90, and cortactin have been de-
scribed as the substrates of HDAC6 (Boyault et al., 2007). In consider-
ation of the fact that the post-translation modiﬁcation of
ubiquitination regulates many proteins in the RIG-I signaling pathway,
HDAC6 may interact with these proteins through polyubiquitin chains
that could serve to coordinate lysine acetylation and ubiquitination.
Our observations show that virus infection induces the HDAC6/RIG-I in-
teraction, and we speculate that this process could be regulated by var-
ious RIG-I modiﬁcations. Our data also indicates that the acetylation of
RIG-I in resting, non-infected cells likely restricts RIG-I from random
self-oligomerization to prevent IFN induction. So far we have not iden-
tiﬁedwhich acetyltransferases may be responsible for RIG-I acetylation.
It is believed that Type B HATs, e.g. HAT1 and MEC-17, are cytoplasmic
actyltransferases and are responsible for acetylating nascent proteins.
These HATs can recognize unacetylated newly synthesized proteins
such that they could be candidate RIG-I acetylases.
In summary, we propose that RIG-I deacetylation by HDAC6 serves
to promote its “signaling-on” conformation initiated by RNA ligand-
binding to RIG-I, resulting in K63-linked polyubiquitination,
deacetylation, and oligomerization of RIG-I leading to activation (Fig.
5). Also, we propose that the unmodiﬁed RIG-I lysine residues, K858
and K909, are important in governing RIG-I activation and signaling
function, consistent with both biochemical and structural models of
RIG-I activation (Saito et al., 2007; Jiang et al., 2011). Upon RNA ligand
binding, RIG-I deacetylation by HDAC6, K63 ubiquitination, and 14-3-
3ε chaperone interactions offer multiple checkpoints for regulation of
the innate immune response. However, deacetylation of RIG-I at the
RD and translocon formation at the CARDs are two independent regula-
tory actions. Deacetylation of RIG-I is critical for its self-oligomerization
via RD and for later CARD-dependent interactions with MAVS to signal
downstream. As our studies implicate a role for HDAC6 at each of
these steps, virus and host processes that affect HDAC6 function are
likely to control RIG-I signaling pathway (Husain and Harrod, 2009).
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